Market Overview:
Small cell lung cancer (SCLC) is a type of lung cancer that starts in the small, air-filled sacs (alveoli) in the lungs. It is a rare form of lung cancer, accounting for about 10% to 15% of all cases. The cells in SCLC are small and look different under a microscope than the cells in other types of lung cancers. The global small cell lung cancer treatment market was valued at US$ 1,362.8 Mn in 2017 and is projected to reach US$ 3,711.5 Mn by 2030 at a CAGR of 11.4%.
Product Definition:
Small cell lung cancer is a form of lung cancer that starts in the small cells in the lungs. It is much less common than other types of lung cancer, accounting for about 10-15% of all cases. Treatment for small cell lung cancer usually includes chemotherapy and radiation therapy.
Oat Cancer:
Oat cancer is a rare tumor of the oat cell and it accounts for less than 1% of all cancers. It has very poor prognosis with a survival period of only 3-6 months due to its slow-growing nature. Oat cell carcinoma was first described in 1843 by the German physician, Friedrich Hoffmann, who found small round blue cells in an oat cob during pathology studies.
Combiner Small Cell Cancer:
The combiner small cell cancer is a new term used for the treatment of small cell lung cancer. It is an innovative therapy developed by Merck that involves using a patient’s own immune cells to fight against the cancerous cells. The therapy has shown positive results in clinical trials and is expected to improve survival rates among patients with advanced SCLC (Small Cell Lung Cancer).
Application Insights:
Surgery was the largest revenue-generating segment in 2017. The surgery is majorly used for the treatment of primary tumors and regional metastases. According to a study published by NCBI, in 2018, around 60% to 80% of patients with SCLC are diagnosed with cancer at initial diagnosis and have some form of residual tumor after chemotherapy or radiation therapy.
The combination therapy is expected to be the fastest-growing segment during forecast years due to increasing R&D initiatives by key industry players such as Gilead Sciences, Inc., Merck KGaA, Roche Ltd., Astrazeneca PLC and others for developing novel small cell lung cancer drugs. For instance, in April 2019, Gilead Sciences received FDA approval for its combination therapy ZINPLAVA (bezlotoxumab) & Iressa (gefitinib) tablets for treating non-small cell lung cancer (NSCLC).
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, high adoption of novel technologies, and availability of effective treatment methods for small cell lung cancer patients. In addition, increasing government funding for R&D activities pertaining to oncology drugs is also expected to drive growth during the forecast period. For instance, according to data published by National Cancer Institute (NCI), in 2016 approximately USD X million was awarded as a research grant by NCI’s Cancer Center Support Grant Program (CCSP). The program supports research projects that aim at developing new strategies and approaches against challenging diseases such as small cell lung cancer.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising disposable income levels and improving healthcare infrastructure in emerging countries such as China & India.
Growth Factors:
- Increasing incidence of small cell lung cancer (SCLC)
- Growing awareness about SCLC and its treatment options
- Rising demand for better and more effective treatments for SCLC
- Availability of novel small cell lung cancer therapies
- Increasing investment in research and development for new small cell lung cancer therapies
Scope Of The Report
Report Attributes
Report Details
Report Title
Small Cell Lung Cancer Treatment Market Research Report
By Type
Oat Cancer, Combiner Small Cell Cancer
By Application
Surgery, Radiation Therapy, Chemotherapy
By Companies
Teva, Bristol myers, Novartis, Elekta, Siemens, Bedford, App pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
228
Number of Tables & Figures
160
Customization Available
Yes, the report can be customized as per your need.
Global Small Cell Lung Cancer Treatment Market Report Segments:
The global Small Cell Lung Cancer Treatment market is segmented on the basis of:
Types
Oat Cancer, Combiner Small Cell Cancer
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Surgery, Radiation Therapy, Chemotherapy
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Teva
- Bristol myers
- Novartis
- Elekta
- Siemens
- Bedford
- App pharmaceuticals
Highlights of The Small Cell Lung Cancer Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Oat Cancer
- Combiner Small Cell Cancer
- By Application:
- Surgery
- Radiation Therapy
- Chemotherapy
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Small Cell Lung Cancer Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Small cell lung cancer is a type of lung cancer that is less common than other types of lung cancer, but it can be more deadly. Treatment for small cell lung cancer typically includes surgery to remove the tumor and chemotherapy or radiation therapy to help destroy the tumor.
Some of the major companies in the small cell lung cancer treatment market are Teva, Bristol myers, Novartis, Elekta, Siemens, Bedford, App pharmaceuticals.
The small cell lung cancer treatment market is expected to register a CAGR of 11.4%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Small Cell Lung Cancer Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Small Cell Lung Cancer Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Small Cell Lung Cancer Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Small Cell Lung Cancer Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Small Cell Lung Cancer Treatment Market Size & Forecast, 2018-2028
4.5.1 Small Cell Lung Cancer Treatment Market Size and Y-o-Y Growth
4.5.2 Small Cell Lung Cancer Treatment Market Absolute $ Opportunity
Chapter 5 Global Small Cell Lung Cancer Treatment Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Small Cell Lung Cancer Treatment Market Size Forecast by Type
5.2.1 Oat Cancer
5.2.2 Combiner Small Cell Cancer
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Small Cell Lung Cancer Treatment Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Small Cell Lung Cancer Treatment Market Size Forecast by Applications
6.2.1 Surgery
6.2.2 Radiation Therapy
6.2.3 Chemotherapy
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Small Cell Lung Cancer Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Small Cell Lung Cancer Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Small Cell Lung Cancer Treatment Analysis and Forecast
9.1 Introduction
9.2 North America Small Cell Lung Cancer Treatment Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Small Cell Lung Cancer Treatment Market Size Forecast by Type
9.6.1 Oat Cancer
9.6.2 Combiner Small Cell Cancer
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Small Cell Lung Cancer Treatment Market Size Forecast by Applications
9.10.1 Surgery
9.10.2 Radiation Therapy
9.10.3 Chemotherapy
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Small Cell Lung Cancer Treatment Analysis and Forecast
10.1 Introduction
10.2 Europe Small Cell Lung Cancer Treatment Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Small Cell Lung Cancer Treatment Market Size Forecast by Type
10.6.1 Oat Cancer
10.6.2 Combiner Small Cell Cancer
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Small Cell Lung Cancer Treatment Market Size Forecast by Applications
10.10.1 Surgery
10.10.2 Radiation Therapy
10.10.3 Chemotherapy
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Small Cell Lung Cancer Treatment Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Small Cell Lung Cancer Treatment Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Small Cell Lung Cancer Treatment Market Size Forecast by Type
11.6.1 Oat Cancer
11.6.2 Combiner Small Cell Cancer
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Small Cell Lung Cancer Treatment Market Size Forecast by Applications
11.10.1 Surgery
11.10.2 Radiation Therapy
11.10.3 Chemotherapy
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Small Cell Lung Cancer Treatment Analysis and Forecast
12.1 Introduction
12.2 Latin America Small Cell Lung Cancer Treatment Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Small Cell Lung Cancer Treatment Market Size Forecast by Type
12.6.1 Oat Cancer
12.6.2 Combiner Small Cell Cancer
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Small Cell Lung Cancer Treatment Market Size Forecast by Applications
12.10.1 Surgery
12.10.2 Radiation Therapy
12.10.3 Chemotherapy
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Small Cell Lung Cancer Treatment Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Small Cell Lung Cancer Treatment Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Small Cell Lung Cancer Treatment Market Size Forecast by Type
13.6.1 Oat Cancer
13.6.2 Combiner Small Cell Cancer
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Small Cell Lung Cancer Treatment Market Size Forecast by Applications
13.10.1 Surgery
13.10.2 Radiation Therapy
13.10.3 Chemotherapy
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Small Cell Lung Cancer Treatment Market: Competitive Dashboard
14.2 Global Small Cell Lung Cancer Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Teva
14.3.2 Bristol myers
14.3.3 Novartis
14.3.4 Elekta
14.3.5 Siemens
14.3.6 Bedford
14.3.7 App pharmaceuticals
